Alex Tretyakov, Ph.D. has been appointed director of process development at Cedarburg Hauser Pharmaceuticals (CHP). Dr. Tretyakov will lead the company's process and analytical development groups, and will join chief scientific officer John Lynch, in providing technical insight into customer projects.
Most recently, Dr. Tretyakov served as vice president of R&D at PCI Synthesis and Cambridge Major Laboratories.
"In his 25-plus years of industry experience Alex has demonstrated a real ability to streamline processes and drive growth via scientific excellence," said CHP chief executive officer Tony Laughrey. "We are counting on Dr. Tretyakov to help accelerate Cedarburg Hauser's growth and are excited to have him on board."